Datavault AI Acquires API Media in All Cash Transaction

(NASDAQ:DVLT), PHILADELPHIA, Oct. 28, 2025 (GLOBE NEWSWIRE) — via IBN – Datavault AI Inc. (Nasdaq: DVLT), a leader in patented data tokenization and monetization technologies, today announced that it has entered into a definitive acquisition agreement to acquire API Media in December of this year. Through API's strength of technology culture and seasoned leadership team, […]

TRREB Applauds Ontario’s New HST Rebate for First-Time Homebuyers

TRREB Applauds Ontario's New HST Rebate for First-Time Homebuyers GlobeNewswire October 28, 2025 TORONTO, Oct. 28, 2025 (GLOBE NEWSWIRE) — The Toronto Regional Real Estate Board (TRREB) applauds the Ontario government's leadership in announcing a new rebate to provide much-needed relief to first-time homebuyers. By removing the full 8 per cent provincial portion of the

Datavault AI Acquires API Media in All Cash Transaction

Datavault AI Acquires API Media in All Cash Transaction Technology provider API selects Datavault AI to continue building its leading culture of tech innovation GlobeNewswire October 28, 2025 PHILADELPHIA, Oct. 28, 2025 (GLOBE NEWSWIRE) — via IBN – Datavault AI Inc. (Nasdaq: DVLT), a leader in patented data tokenization and monetization technologies, today announced that

Molina Healthcare, Inc. (MOH) Investors With Losses May Have Been Misled by The Company – Contact BFA Law Before December 2 Class Action Deadline

NEW YORK CITY, NY / ACCESS Newswire / October 28, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Molina Healthcare, Inc. (NYSE:MOH) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Molina, you are

MoonLake Immunotherapeutics (MLTX) Investors with Losses May Have Been Misled by The Company – Contact BFA Law before December 15 Class Action Deadline

NEW YORK CITY, NY / ACCESS Newswire / October 28, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ:MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged

The Capital Link Independent Investigative Report: Ethical and Factual Failures in Ethan Rothstein’s Reporting and Bisnow’s Editorial Oversight

New York, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) — This independent investigative report examines a pattern of factual and ethical failures in the reporting of Ethan Rothstein, Deputy Managing Editor at Bisnow. Through detailed analysis of his published work from 2023-2025, as well as Bisnow's own public corrections and relevant court filings, this report finds

The Capital Link Independent Investigative Report: Ethical and Factual Failures in Ethan Rothstein’s Reporting and Bisnow’s Editorial Oversight

The Capital Link Independent Investigative Report: Ethical and Factual Failures in Ethan Rothstein's Reporting and Bisnow's Editorial Oversight GlobeNewswire October 28, 2025 New York, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) — This independent investigative report examines a pattern of factual and ethical failures in the reporting of Ethan Rothstein, Deputy Managing Editor at Bisnow. Through

Lost Money on KBR, Inc. (KBR)? Contact Levi & Korsinsky Before November 18, 2025 to Join Class Action

NEW YORK, NY / ACCESS Newswire / October 28, 2025 / If you suffered a loss on your KBR, Inc. (NYSE:KBR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/kbr-inc-lawsuit-submission-form?prid=174380&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders

(NasdaqGM:RNA), NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair to Avidity shareholders. Halper Sadeh encourages Avidity shareholders to click here to learn more about their legal

Scroll to Top